The capital turnover (annual revenue relative to shareholder's equity) for MESO is 0.03 -- better than just 10.03% of US stocks.
MESO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 4,006.76 -- higher than 99.09% of US-listed equities with positive expected earnings growth.
With a price/sales ratio of 76.51, Mesoblast Ltd has a higher such ratio than 97.21% of stocks in our set.
If you're looking for stocks that are quantitatively similar to Mesoblast Ltd, a group of peers worth examining would be JKHY, DRRX, FOXF, LQDT, and TCX.
MESO's SEC filings can be seen here. And to visit Mesoblast Ltd's official web site, go to www.mesoblast.com.
Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.
Hello, and welcome to the financial results for the period ended March 31, 2020, and corporate update for Mesoblast. Before we begin, let me remind you that in today's conference call the company will be making forward-looking statements that represent the company's intentions, expectations or beliefs concerning future events. In addition, any forward-looking statements represent the company's views only as of the date of this webcast and should not be relied upon as representing the company's views of any subsequent date.
In an interim performance update focusing on the past 9 months, dual-listed cellular medicines company Mesoblast (ASX: MSB) reported it had achieved a “strong financial position” and made progress with its lead drug remestemcel-L, a drug being developed to treat severe cytokine release syndromes.